Feature | July 12, 2013

Patient Receives MitraClip Device to Treat Mitral Regurgitation Symptoms as Part of COAPT Trial

Scripps Clinic is only trial site in San Diego to offer MitraClip device

July 12, 2013 — Virginia Anderer, a Chicago native living in southern California, was the first patient in San Diego and at Scripps Health to receive a MitraClip as part of the clinical outcomes assessment of the MitraClip Percutaneous Therapy for High Surgical Risk Patients (COAPT) trial. The MitraClip device is designed to reduce significant mitral regurgitation by clipping together the leaflets of the mitral valve. 

“Traditionally, there have been no good treatment options available for patients like Mrs. Anderer, who suffer from significant mitral regurgitation and are too high risk for surgery,” said Matthew Price, M.D., who implanted the MitraClip device as principal investigator for COAPT at Scripps Clinic. “Now, using advanced imaging techniques and catheters, we were able to repair Mrs. Anderer’s leaking heart valve without the need for open-heart surgery.”

Mitral regurgitation (MR) is the most common type of heart valve defect, affecting approximately one in 10 people aged 75 years and older. The condition occurs when the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart during each heartbeat.

To maintain an adequate forward flow of blood throughout the body, the heart compensates by increasing the size of the left ventricle, the main pumping chamber of the heart. This requires the heart to work harder, and may ultimately lead to irregular heartbeats, stroke, heart attack or death. MR may also lead to heart failure, a potentially deadly condition that occurs when the heart is unable to pump sufficiently to distribute blood flow to meet the needs of the body.

In Anderer’s case, she was experiencing significant shortness of breath that was getting progressively worse and having a detrimental effect on her quality of life. She was no longer benefiting from medication, and because of her age and medical history, open-heart surgery was not an option. The retired nurse underwent the procedure on June 14 at Scripps Green Hospital and was discharged two days later.

Manufactured by Abbott, MitraClip therapy is designed to reduce MR and provide clinical and quality-of-life benefits for patients suffering from the debilitating symptoms of significant MR by clipping together a portion of the leaflets of the mitral valve. The device is delivered to the heart through the femoral vein in the leg.

“By reducing MR, the hope is that this therapy may allow the heart to recover from overwork and improve function, potentially halting the progression of heart failure and enabling patients to live a higher-quality life,” said Price.

MitraClip is currently under review by the U.S. Food and Drug Administration (FDA), and is commercially available in approximately 30 countries. The European Society of Cardiology (ESC) 2012 heart failure guidelines and the ESC/European Association for Cardio-Thoracic Surgery 2012 guidelines for the management of valvular heart disease specify the MitraClip device as a treatment option for high surgical risk patients with MR.

For more information: www.scripps.org, www.abbottvascular.com

Related Content

Mitralign, Series E funding, Trialign, MPAS
News | Heart Valve Technology| May 23, 2016
Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing.
TAVR outcomes, aortic valve gradient, JACC study
News | Heart Valve Technology| May 23, 2016
Patients with a combination of left ventricular dysfunction and low aortic valve gradient have higher mortality rates...
Direct Flow Medical, TAVR device, DISCOVER trial, three-year results, EuroPCR 2016
News | Heart Valve Technology| May 20, 2016
Direct Flow Medical Inc. presented three-year results from its prospective, multicenter DISCOVER Trial at the EuroPCR...
RDAVR, aortic valve replacement, Edwards Intuity, TRANSFORM Trial, AATS meeting
News | Heart Valve Technology| May 18, 2016
The TRANSFORM trial was designed to evaluate the safety and performance of an investigational rapid deployment aortic...
NeoChord, DS1000 System, FDA approval, U.S. pivotal trial
News | Heart Valve Technology| May 17, 2016
NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
4Tech Inc., TriCinch transcatheter tricuspid valve repair device, Jean-Claude Laborde

Image courtesy of 4Tech Inc.

News | Heart Valve Technology| May 16, 2016
4Tech Inc. announced its partnership with Jean-Claude Laborde, M.D., as a research and development (R&D) and...

A Medtronic CoreValve TAVR device being deployed under angiographic image guidance.

 

Feature | Heart Valve Technology| May 16, 2016
 
aortic valve reconstruction, surgery, PinnacleHealth, Pennsylvania
News | Cardiovascular Surgery| May 04, 2016
Three PinnacleHealth patients recently underwent a new procedure for aortic valve reconstruction using the patients'...
Feature | Business| April 28, 2016 | Dave Fornell
 
Overlay Init